Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Tenaya Therapeutics (TNYA)
NASDAQ:TNYA
RESEARCH TOOLSreports
TNYA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.86 - $7.01
Previous CloseN/A
Volume1.07M
Average Volume (3M)2.03M
Market Cap
$95.06M
Enterprise Value$101.36M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta3.51
Next Earnings
Mar 25, 2025EPS Estimate
-0.31Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.48
Shares Outstanding79,220,510
10 Day Avg. Volume2,079,716
30 Day Avg. Volume2,029,499
Standard Deviation0.33
R-Squared0.17
Alpha-0.04
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-1.20
P/FCF Ratio0.00
Enterprise Value/Market Cap1.07
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-11.67
Enterprise Value/Ebitda-0.89
Forecast
1Y Price Target
$23.00Price Target Upside1816.67% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
---
Tenaya Therapeutics News
PremiumCompany Announcements
Tenaya Therapeutics Appoints Interim Accounting Officer
PremiumCompany Announcements
Tenaya Therapeutics Reprices Underwater Stock Options
---
Bulls Say, Bears Say
Bulls Say
Clinical AdvancementsThe company recently unveiled positive initial data from its Phase 1b study of TN-201, MyPeak-1.
External ValidationTenaya Therapeutics received an $8 million grant from the California Institute of Regenerative Medicine to support the clinical trial costs for its ongoing study of TN-401.
Strategic ExpansionThe company plans to activate its first international RIDGE-1 clinical site, indicating expansion beyond the U.S.
Bears Say
Awaited ClarityClarity on endpoints in nonobstructive MYBPC3-HCM is awaited.
Cash Runway ConcernsConcerns on cash runway overhang shares into this year's data updates.
Stock ReactionInvestors were left wanting more from this first cut, and the negative stock reaction reflects these expectations.
---
Ownership Overview
30.89% Insiders
11.55% Mutual Funds
26.56% Other Institutional Investors
24.02% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
TNYA FAQ
What was Tenaya Therapeutics’s price range in the past 12 months?
Tenaya Therapeutics lowest stock price was $0.86 and its highest was $7.01 in the past 12 months.
What is Tenaya Therapeutics’s market cap?
Tenaya Therapeutics’s market cap is $95.06M.
When is Tenaya Therapeutics’s upcoming earnings report date?
Tenaya Therapeutics’s upcoming earnings report date is Mar 25, 2025 which is in 36 days.
How were Tenaya Therapeutics’s earnings last quarter?
Tenaya Therapeutics released its earnings results on Nov 06, 2024. The company reported -$0.3 earnings per share for the quarter, beating the consensus estimate of -$0.368 by $0.068.
Is Tenaya Therapeutics overvalued?
According to Wall Street analysts Tenaya Therapeutics’s price is currently Undervalued.
Does Tenaya Therapeutics pay dividends?
Tenaya Therapeutics does not currently pay dividends.
What is Tenaya Therapeutics’s EPS estimate?
Tenaya Therapeutics’s EPS estimate is -0.31.
How many shares outstanding does Tenaya Therapeutics have?
Tenaya Therapeutics has 79,220,510 shares outstanding.
What happened to Tenaya Therapeutics’s price movement after its last earnings report?
Tenaya Therapeutics reported an EPS of -$0.3 in its last earnings report, beating expectations of -$0.368. Following the earnings report the stock price went up 12.108%.
Which hedge fund is a major shareholder of Tenaya Therapeutics?
Among the largest hedge funds holding Tenaya Therapeutics’s share is RA Capital Management. It holds Tenaya Therapeutics’s shares valued at 13M.
---
Tenaya Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$23.00 (1816.67% Upside)
$23.00 (1816.67% Upside)
Hedge Fund Trend
Decreased
By 743.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $4.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.5%
Last 30 Days ▼ 4.2%
Last 30 Days ▼ 4.2%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-78.18%
12-Months-Change
Fundamentals
Return on Equity
-84.49%
Trailing 12-Months
Asset Growth
-27.31%
Trailing 12-Months
Company Description
Tenaya Therapeutics
Tenaya Therapeutics Inc is a preclinical stage biotechnology company focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. It is advancing product candidates from three product platforms: gene therapy, cellular regeneration, and precision medicine.
---
TNYA Stock 12 Month Forecast
Average Price Target
$23.00
▲(1816.67% Upside)
Technical Analysis
Sangamo Biosciences
―
Editas Medicine
―
Intellia Therapeutics
―
Crispr Therapeutics AG
―
Beam Therapeutics
―
Best Analysts Covering TNYA
1 Year
1 Year Success Rate
3/11 ratings generated profit
1 Year Average Return
-34.34%
reiterated a buy rating 3 months ago
Copying Whitney Ijem's trades and holding each position for 1 Year would result in 27.27% of your transactions generating a profit, with an average return of -34.34% per trade.
---